Biodesics (BDSX) Q3 2025: Primary Care Test Orders Jump 75% as Sales Expansion Drives Adoption

2025-11-03 | By EarningsIQ Research

Biodesics accelerated its lung diagnostics adoption by expanding into primary care, driving a marked shift in test order growth and sales force productivity. The company’s execution on digital ordering and operational leverage is translating into improved margins and a path to EBITDA positivity in Q4. With new product partnerships and a robust pipeline, Biodesics is positioning for broader payer and provider adoption into 2026.

Summary

• Primary Care Penetration Accelerates: Lung diagnostic orders from primary care surged, validating the expanded sales strategy.
• Margin and Productivity Gains: Digital ordering and operational discipline supported margin expansion and improved rep productivity.
• Pipeline and Partnerships Set Up 2026: Bio-Rad, Thermo Fisher, and Memorial Sloan Kettering collaborations signal future product catalysts.

Business Overview

Biodesics is a diagnostics company focused on lung health, commercializing multimodal, AI-driven tests that integrate genomics, proteomics, and radiomics to enable earlier, more accurate cancer detection and management. The company’s core revenue comes from its lung diagnostic testing, with additional growth from development services provided to biopharma and life science partners. Major segments include Lung Diagnostics (the bulk of revenue) and Development Services (rapidly growing, but still a minority share).

Performance Analysis

Biodesics delivered robust top-line growth, with total revenue up 20% year-over-year, driven by both volume and pricing gains in lung diagnostics and a near doubling of development services revenue. Lung diagnostic testing remains the company’s anchor, accounting for the vast majority of revenue and showing 13% test volume growth alongside a 7% increase in average revenue per test, reflecting improved payer coverage and revenue cycle execution.

Gross margin expanded to 81%, up 400 basis points, even as the company scaled its sales force and absorbed higher supply costs. Notably, SG&A rose only modestly year-over-year and declined sequentially, demonstrating operational leverage as sales rep headcount increased by 15%. R&D spend ticked up on a year-over-year basis due to pipeline investments, but fell sequentially. Net loss and adjusted EBITDA both improved materially, with the company on track for adjusted EBITDA breakeven in Q4. Cash management was disciplined, with a temporary AR build offset by ATM facility inflows and strong collections in Q4.

• Primary Care Expansion Drives Test Growth: Orders from primary care jumped 75% YoY, now representing 11% of total tests versus 4% pre-expansion.
• Development Services Momentum: Revenue up 97% YoY, with $12.9 million in contracted backlog, a new high.
• Margin Structure Strengthens: 400 bps gross margin improvement, supported by digital ordering and process enhancements.

The company’s ability to grow volumes, expand pricing, and manage costs in tandem reflects increasing commercial and operational maturity, while development services provide optionality and future upside.

Executive Commentary

Strategic Positioning

1. Primary Care Channel Penetration

Biodesics’ deliberate expansion into primary care is unlocking a previously underpenetrated segment, with warm handoffs from pulmonologists catalyzing adoption and improving early cancer detection rates. This strategic move not only broadens the addressable market but also increases test completion rates by enabling on-site blood draws and digital ordering.

2. Sales Force Scaling and Productivity

The company’s sales team grew from 65 to 85 reps in three quarters, with plans to reach up to 97 in Q4. Management targets a return to $1 million+ in sales per rep productivity, supported by a complementary team structure and territory optimization. The ramp for new reps has been consistent, and incremental hires are expected to further drive volume and geographic reach.

3. Digital and Operational Leverage

Digital test ordering through the Biodesics portal and EHR integrations rose 43% YoY, streamlining workflows and raising customer retention. This digital push, combined with process improvements in revenue cycle management, is supporting both top-line and margin gains.

4. Pipeline and Partnership Catalysts

Strategic collaborations with Bio-Rad, Thermo Fisher, and Memorial Sloan Kettering are advancing the product pipeline, including a unique MRD (minimal residual disease) test and expanded indications for Veristrat. These partnerships provide validation and future growth levers, with updates expected at industry meetings and in 2026 product launches.

5. First Mover Advantage in Lung Nodule Management

Biodesics’ leadership in lung nodule diagnostics, supported by real-world evidence and health economics data, positions the company to benefit from broader lung cancer screening and guideline adoption as awareness and payer support increase.

Key Considerations

This quarter marked a turning point in Biodesics’ commercial execution, with clear signals that the primary care channel and digital initiatives are scaling. For investors, the interplay of sales force expansion, operational discipline, and pipeline progress will determine the company’s ability to sustain growth and reach profitability.

Key Considerations:

• Primary Care Adoption Momentum: Early proof points support further penetration, but sustained growth depends on ongoing provider education and workflow integration.
• Sales Rep Productivity Trajectory: Management’s $1 million per rep target is ambitious and will be a key metric for monitoring ROI on the expanding sales team.
• Payer Coverage and ASP Stability: Recent increases in average selling price (ASP) tied to improved Medicare Advantage payments need to be watched for consistency.
• Pipeline Visibility: R&D partnerships and upcoming data releases could drive investor sentiment if new products approach commercialization.
• Cash Flow and Capital Needs: While management expresses confidence, cash burn and timing of collections remain important for funding growth without further dilution.

Risks

Execution risk remains around scaling the sales force and achieving targeted productivity, particularly as Biodesics moves deeper into primary care, a segment with different buying dynamics than specialist pulmonology. Payer reimbursement stability is critical, especially with ongoing negotiations for older Medicare Advantage claims. Competition in lung diagnostics could intensify, and guideline or regulatory changes may alter the adoption curve or reimbursement landscape.

Forward Outlook

For Q4 2025, Biodesics guided to:

• Adjusted EBITDA positivity based on current momentum and cost control
• Sales force headcount of 93 to 97 reps, with continued territory expansion

For full-year 2025, management raised guidance:

• Revenue range of $84 to $86 million, up from prior outlook

Management highlighted several factors that support this guidance:

• Ongoing primary care adoption and digital ordering uptake
• Continued strong demand in development services and a record contracted backlog

Takeaways

Biodesics is executing a multi-pronged growth strategy, with tangible gains from primary care channel expansion, digital adoption, and operational leverage. The company’s disciplined cost control and pipeline partnerships provide a credible path to profitability and future product catalysts.

• Primary Care Test Growth: 75% YoY increase in orders signals the channel is scaling, with improved early detection outcomes reported.
• Margin and Productivity Leverage: Digital ordering and disciplined SG&A are driving margin expansion even as the sales force grows.
• 2026 Pipeline Watch: Investor focus will shift to product launches and partnership milestones as Biodesics leverages its R&D collaborations for new growth vectors.

Conclusion

Biodesics’ Q3 results reflect a company in operational transition, successfully expanding its commercial reach while maintaining financial discipline. Sustained execution in primary care, stable payer support, and pipeline progress will be critical as the company approaches profitability and broader adoption in 2026.

Industry Read-Through

The rapid adoption of lung diagnostics in primary care underscores a broader trend toward decentralizing advanced testing and integrating AI-driven diagnostics into frontline medicine. As digital ordering and workflow integration become table stakes, competitors will need to demonstrate similar operational agility and payer engagement. The surge in development services revenue and cross-institutional partnerships signals rising demand for multi-omic, AI-enabled diagnostics across oncology and chronic disease management. Winners in this space will combine clinical evidence, digital enablement, and commercial execution to capture share as payer and provider adoption accelerates.

BDSX Health Care Diagnostics Lung Cancer Primary Care Digital Health Pipeline Reimbursement